

**CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND**  
**INSTRUCTIONS FOR ENTRY**

**IN THE SPECIFICATION:**

Q1 As a result of these procedures, the disease specific markers namely sugar uptake ABC transporter from permease protein Sinorhizobium melloti having a molecular weight of about 1623.8425 daltons and having a sequence identified as SEQ ID NO: 1, HP AC024778 having a molecular weight of about 1552 daltons and a sequence identified as SEQ ID NO: 2, related to Type II diabetes were found.

**IN THE CLAIMS:**

Q2 Claim 1. A biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2 or at least one analyte thereof useful in indicating at least one particular disease state.

Claim 18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

Q3 at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2 or at least one analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule;

23.1  
cont

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

---

24

Claim 29. Polyclonal antibodies produced against a marker sequence ID selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2 or at least one analyte thereof in at least one animal host.

---

25

Claim 30. An antibody that specifically binds a biopolymer including a marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2 or at least one analyte thereof.

---

Claim 33. A process for identifying therapeutic avenues related to a disease state comprising:

26

conducting an analysis as provided by the kit of claim 18; and  
interacting with a biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2 or at least one analyte thereof;  
whereby therapeutic avenues are developed.

---

27

Claim 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2 or at least one analyte thereof.

---